BioSpace News Archive

Horizon Therapeutics plc (Nasdaq: HZNP) today announced the closing of its underwritten public offering of 13,570,000 of its ordinary shares at a price to the public of $71.00 per share.

Seasoned scientific leader to head the contract research organization’s bioanalytical operations in Lincoln, NE.

India Globalization Capital (“IGC” or the “Company”) (NYSE American: IGC) announced today that on July 30, 2020, the U.S. Food and Drug Administration (FDA) notified IGC that it has authorized the Company to initiate a Phase 1 human trial study for the Company’s investigational cannabinoid formulation for the treatment of patients suffering from mild to severe dementia due to Alzheimer’s disease

Mirum Pharmaceuticals, Inc. announced that the Compensation Committee of Mirum’s Board of Directors granted a non-qualified stock option award to purchase an aggregate of 25,000 shares of common stock to one new employee under Mirum’s 2020 Inducement Plan.

Strong organic growth across all key product lines, including recently acquired IXINITY ® Generated $4.1 million of cash flow from operations Management to host conference call at 8:00 AM ET on Wednesday, August 12, 2020 TORONTO, CHICAGO and MONTREAL, Aug. 11, 2020 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP, OTCQX: PDDPF) today provided a business update and announced its financial and operating results for the three-month period ended

HJF Medical Research International (HJFMRI), a wholly owned subsidiary of The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. (HJF) , was awarded $1.3M by the Bill & Melinda Gates Foundation to support antenatal, intrapartum and postnatal care in the Kenya Child Health and Mortality Surveillanc

New U.S. government award up to $1.525 billion for 100 million doses Option granted to U.S. government to purchase up to an additional 400 million doses CAMBRIDGE, Mass.--( BUSINESS WIRE )-- Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that the U.S. government has secured 100 million doses of m

Marinus Pharmaceuticals, Inc., a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, announced the grant of inducement awards to seven new employees.

Pacific Biosciences of California, Inc. announced that it has priced its previously announced underwritten public offering of 19,430,000 shares of its common stock at a price to the public of $4.47 per share.

Adverum Biotechnologies, Inc. (Nasdaq:ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced that it has commenced an underwritten public offering of $200 million of its common stock.